메뉴 건너뛰기




Volumn 7, Issue 4, 2012, Pages 249-257

Prevention and treatment of myeloma bone disease

Author keywords

Activin; Bisphosphonates; Bone disease; Clodronate; Denosumab; Dickkopf 1; Multiple myeloma; Pamidronate; Receptor activator of nuclear factor ?B ligand (RANKL); Sclerostin; Sotatercept; Treatment; Zoledronic acid

Indexed keywords

ACTIVIN A; AMINO TERMINAL TELOPEPTIDE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BHQ 880; BORTEZOMIB; CARBOXY TERMINAL TELOPEPTIDE; CARFILZOMIB; CLODRONIC ACID; DENOSUMAB; DICKKOPF 1 PROTEIN; ETIDRONIC ACID; IBANDRONIC ACID; LENALIDOMIDE; MELPHALAN; NEUTRALIZING ANTIBODY; OPROZOMIB; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PLACEBO; POMALIDOMIDE; PREDNISOLONE; ROMOSOZUMAB; SCLEROSTIN; SOTATERCEPT; THALIDOMIDE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

EID: 84872202889     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-012-0135-0     Document Type: Article
Times cited : (13)

References (82)
  • 1
    • 0037216353 scopus 로고    scopus 로고
    • Review of 1027 patients with newly diagnosed multiple myeloma
    • Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21-33.
    • (2003) Mayo Clin Proc. , vol.78 , pp. 21-23
    • Kyle, R.A.1    Gertz, M.A.2    Witzig, T.E.3
  • 4
    • 0042822157 scopus 로고    scopus 로고
    • Activin a stimulates ikappab-Alpha/nfkappab and rank expression for osteoclast differentiation, but not akt survival pathway in osteoclast precursors
    • Sugatani T, Alvarez UM, Hruska KA. Activin A stimulates IkappaB-Alpha/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J Cell Biochem. 2003;90:59-67.
    • (2003) J Cell Biochem. , vol.90 , pp. 59-57
    • Sugatani, T.1    Alvarez, U.M.2    Hruska, K.A.3
  • 6
    • 84863959463 scopus 로고    scopus 로고
    • Sclerostin: A possible target for the management of cancer-induced bone disease
    • Gkotzamanidou M, Dimopoulos MA, Kastritis E, et al. Sclerostin: a possible target for the management of cancer-induced bone disease. Expert Opin Ther Targets. 2012;16:761-9.
    • (2012) Expert Opin Ther Targets. , vol.16 , pp. 761-769
    • Gkotzamanidou, M.1    Dimopoulos, M.A.2    Kastritis, E.3
  • 7
    • 0032956189 scopus 로고    scopus 로고
    • Economic impact of using clodronate in the management of patients with multiple myeloma
    • Bruce NJ, McCloskey EV, Kanis JA, et al. Economic impact of using clodronate in the management of patients with multiple myeloma. Br J Haematol. 1999;104:358-64.
    • (1999) Br J Haematol. , vol.104 , pp. 358-354
    • Bruce, N.J.1    McCloskey, E.V.2    Kanis, J.A.3
  • 9
    • 35048875471 scopus 로고    scopus 로고
    • Pathologic fractures correlate with reduced survival in patients with malignant bone disease
    • DOI 10.1002/cncr.22991
    • Saad F, Lipton A, Cook R, et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110:1860-7. (Pubitemid 47557312)
    • (2007) Cancer , vol.110 , Issue.8 , pp. 1860-1867
    • Saad, F.1    Lipton, A.2    Cook, R.3    Chen, Y.-M.4    Smith, M.5    Coleman, R.6
  • 10
    • 5444262558 scopus 로고    scopus 로고
    • Bisphosphonates: Clinical experience
    • Coleman RE. Bisphosphonates: clinical experience. Oncologist. 2004;9:14-27.
    • (2004) Oncologist. , vol.9 , pp. 14-17
    • Coleman, R.E.1
  • 11
    • 0025916366 scopus 로고
    • Effect of daily etidronate on the osteolysis of multiple myeloma
    • Belch AR, Bergsagel DE,Wilson K, et al. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol. 1991;9:1397-402.
    • (1991) J Clin Oncol. , vol.9 , pp. 1397-1390
    • Belch, A.R.1    Bergsagel, D.E.2    Wilson, K.3
  • 12
    • 0027331171 scopus 로고
    • Treatment of multiple myeloma with etidronate: Results of a multicentre double-blind study
    • Daragon A, Humez C, Michot C, et al. Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Eur J Med. 1993;2:449-52.
    • (1993) Eur J Med. , vol.2 , pp. 449-442
    • Daragon, A.1    Humez, C.2    Michot, C.3
  • 14
    • 0026646339 scopus 로고
    • Randomised, placebocontrolled multicentre trial of clodronate in multiple myeloma
    • Lahtinen R, Laakso M, Palva I, et al. Randomised, placebocontrolled multicentre trial of clodronate in multiple myeloma. Lancet. 1992;40:1049-52.
    • (1992) Lancet. , vol.40 , pp. 1049-1042
    • Lahtinen, R.1    Laakso, M.2    Palva, I.3
  • 15
    • 0028106385 scopus 로고
    • Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in muliple myeloma
    • Laakso M, Lahtinen R, Virkkunen P, et al. Subgroup and costbenefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Br J Haematol. 1994;87:725-9. (Pubitemid 24264643)
    • (1994) British Journal of Haematology , vol.87 , Issue.4 , pp. 725-729
    • Laakso, M.1    Lahtinen, R.2    Virkkunen, P.3    Elomaa, I.4
  • 16
    • 0031911183 scopus 로고    scopus 로고
    • A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Mrc working party on leukaemia in adults
    • McCloskey EV, MacLennan IC, Drayson MT, et al. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haematol. 1998;100:317-25.
    • (1998) Br J Haematol. , vol.100 , pp. 317-315
    • McCloskey, E.V.1    MacLennan, I.C.2    Drayson, M.T.3
  • 17
    • 0034937438 scopus 로고    scopus 로고
    • Long-Term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma
    • McCloskey EV, Dunn JA, Kanis JA, et al. Long-Term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol. 2001;113:1035-43.
    • (2001) Br J Haematol. , vol.113 , pp. 1035-1033
    • McCloskey, E.V.1    Dunn, J.A.2    Kanis, J.A.3
  • 18
    • 9044219839 scopus 로고    scopus 로고
    • Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma aredia study group
    • Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334:488-93.
    • (1996) N Engl J Med. , vol.334 , pp. 488-483
    • Berenson, J.R.1    Lichtenstein, A.2    Porter, L.3
  • 19
    • 6844252283 scopus 로고    scopus 로고
    • Long-Term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma aredia study group
    • Berenson JR, Lichtenstein A, Porter L, et al. Long-Term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16:593-602.
    • (1998) J Clin Oncol. , vol.16 , pp. 593-590
    • Berenson, J.R.1    Lichtenstein, A.2    Porter, L.3
  • 20
  • 21
    • 77957332677 scopus 로고    scopus 로고
    • Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (nordic myeloma study group): A double-blind, randomised controlled trial
    • The only randomized study which compared two different dosages of pamidronate in myeloma patients
    • Gimsing P, Carlson K, Turesson I, et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol. 2010;11:973-82. The only randomized study which compared two different dosages of pamidronate in myeloma patients.
    • (2010) Lancet Oncol. , vol.11 , pp. 973-972
    • Gimsing, P.1    Carlson, K.2    Turesson, I.3
  • 22
    • 0035312469 scopus 로고    scopus 로고
    • Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases
    • Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91:1191-200.
    • (2001) Cancer. , vol.91 , pp. 1191-1190
    • Berenson, J.R.1    Rosen, L.S.2    Howell, A.3
  • 23
    • 0035463593 scopus 로고    scopus 로고
    • Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase iii, double-blind, comparative trial
    • Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377-87.
    • (2001) Cancer J. , vol.7 , pp. 377-377
    • Rosen, L.S.1    Gordon, D.2    Kaminski, M.3
  • 24
    • 10744233021 scopus 로고    scopus 로고
    • Long-Term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial
    • Rosen LS, Gordon D, Kaminski M, et al. Long-Term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735-44.
    • (2003) Cancer. , vol.98 , pp. 1735-1734
    • Rosen, L.S.1    Gordon, D.2    Kaminski, M.3
  • 25
    • 78650174738 scopus 로고    scopus 로고
    • First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (mrc myeloma ix): A randomised controlled trial
    • The biggest randomized study in the field of bisphosphonates for the treatment of myeloma-related bone disease which compared oral clodronate and zoledronic acid. The study confirmed the superiority of zoledronic acid over clodronate not only regarding skeletal-related events but also regarding survival
    • Morgan GJ, Davies FE, Gregory WM, et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376:1989-99. The biggest randomized study in the field of bisphosphonates for the treatment of myeloma-related bone disease which compared oral clodronate and zoledronic acid. The study confirmed the superiority of zoledronic acid over clodronate not only regarding skeletal-related events but also regarding survival.
    • (2010) Lancet. , vol.376 , pp. 99
    • Morgan, G.J.1    Davies, F.E.2    Gregory, W.M.3
  • 26
    • 79960891058 scopus 로고    scopus 로고
    • Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (mrc myeloma ix): Secondary outcomes from a randomised controlled trial
    • Morgan GJ, Child JA, Gregory WM, et al. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol. 2011;12:743-52.
    • (2011) Lancet Oncol. , vol.12 , pp. 743-742
    • Morgan, G.J.1    Child, J.A.2    Gregory, W.M.3
  • 27
    • 84862524640 scopus 로고    scopus 로고
    • Effects of induction and maintenance plus long-Term bisphosphonates on bone disease in patients with multiple myeloma: Mrc myeloma ix trial
    • The updated analysis of the reference 25 which showed that the beneficial effect of zoledronic acid over clodronate continues even after two years following initiation of bisphosphonate therapy
    • Morgan GJ, Davies FE, Gregory WM, et al. Effects of induction and maintenance plus long-Term bisphosphonates on bone disease in patients with multiple myeloma: MRC Myeloma IX trial. Blood. 2012;119:5374-83. The updated analysis of the reference 25 which showed that the beneficial effect of zoledronic acid over clodronate continues even after two years following initiation of bisphosphonate therapy.
    • (2012) Blood. , vol.119 , pp. 5374-5373
    • Morgan, G.J.1    Davies, F.E.2    Gregory, W.M.3
  • 28
    • 34347260332 scopus 로고    scopus 로고
    • American society of clinical oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma
    • Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25:2464-72.
    • (2007) J Clin Oncol. , vol.25 , pp. 2464-2462
    • Kyle, R.A.1    Yee, G.C.2    Somerfield, M.R.3
  • 29
    • 69449108135 scopus 로고    scopus 로고
    • The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the european myeloma network
    • Recommendations of the European Myeloma Network for the tretament of myeloma-related bone disease
    • Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol. 2009;20:1303-17. Recommendations of the European Myeloma Network for the tretament of myeloma-related bone disease.
    • (2009) Ann Oncol. , vol.20 , pp. 1303-1307
    • Terpos, E.1    Sezer, O.2    Croucher, P.I.3
  • 31
    • 33745792743 scopus 로고    scopus 로고
    • Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid
    • Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006;91:968-71.
    • (2006) Haematologica. , vol.91 , pp. 968-961
    • Dimopoulos, M.A.1    Kastritis, E.2    Anagnostopoulos, A.3
  • 32
    • 33747426633 scopus 로고    scopus 로고
    • Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients
    • DOI 10.1111/j.1365-2141.2006.06230.x
    • Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol. 2006;134:620-3. (Pubitemid 44253605)
    • (2006) British Journal of Haematology , vol.134 , Issue.6 , pp. 620-623
    • Zervas, K.1    Verrou, E.2    Teleioudis, Z.3    Vahtsevanos, K.4    Banti, A.5    Mihou, D.6    Krikelis, D.7    Terpos, E.8
  • 33
    • 58049204529 scopus 로고    scopus 로고
    • Natural history of osteonecrosis of the jaw in patients with multiple myeloma
    • Badros A, Terpos E, Katodritou E, et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol. 2008;26:5904-9.
    • (2008) J Clin Oncol. , vol.26 , pp. 5904-5909
    • Badros, A.1    Terpos, E.2    Katodritou, E.3
  • 34
    • 58949104001 scopus 로고    scopus 로고
    • Reduction of osteonecrosis of the jaw (onj) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
    • An important study which showed for the first time that the implementation of dental preventive measures reduces the incidence of ONJ in myeloma patients who receive bisphosphonates
    • Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2009;20:117-20. An important study which showed for the first time that the implementation of dental preventive measures reduces the incidence of ONJ in myeloma patients who receive bisphosphonates.
    • (2009) Ann Oncol. , vol.20 , pp. 117-110
    • Dimopoulos, M.A.1    Kastritis, E.2    Bamia, C.3
  • 35
    • 57049173860 scopus 로고    scopus 로고
    • Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates
    • Montefusco V, Gay F, Spina F, et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma. 2008;49:2156-62.
    • (2008) Leuk Lymphoma. , vol.49 , pp. 2156-2152
    • Montefusco, V.1    Gay, F.2    Spina, F.3
  • 36
    • 29144436466 scopus 로고    scopus 로고
    • Managing the care of patients with bisphosphonate-Associated osteonecrosis: An american academy of oral medicine position paper
    • Migliorati CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate-Associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005;136:1658-68.
    • (2005) J Am Dent Assoc. , vol.136 , pp. 1658-1658
    • Migliorati, C.A.1    Casiglia, J.2    Epstein, J.3
  • 37
    • 33947193435 scopus 로고    scopus 로고
    • Multiple myeloma. Clinical practice guidelines in oncology
    • Anderson KC, Alsina M, Bensinger W, et al. Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007;5:118-47.
    • (2007) J Natl Compr Canc Netw. , vol.5 , pp. 118-117
    • Anderson, K.C.1    Alsina, M.2    Bensinger, W.3
  • 38
    • 21044454594 scopus 로고    scopus 로고
    • Esmo minimum clinical recommendations for diagnosis, treatment and follow-up of multiple myeloma
    • ESMO Guidelines Task Force
    • Harrouseau JL, Greil R, Kloke O. ESMO Guidelines Task Force. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma. Ann Oncol. 2005;16:45-7.
    • (2005) Ann Oncol. , vol.16 , pp. 45-47
    • Harrouseau, J.L.1    Greil, R.2    Kloke, O.3
  • 39
    • 33746855407 scopus 로고    scopus 로고
    • Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma
    • Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc. 2006;81:1047-53.
    • (2006) Mayo Clin Proc. , vol.81 , pp. 1047-1043
    • Lacy, M.Q.1    Dispenzieri, A.2    Gertz, M.A.3
  • 40
    • 34047200362 scopus 로고    scopus 로고
    • Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement [1]
    • Durie BG. Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc. 2007;82:516-57. (Pubitemid 46543476)
    • (2007) Mayo Clinic Proceedings , vol.82 , Issue.4 , pp. 516-517
    • Durie, B.G.M.1
  • 41
    • 54049124120 scopus 로고    scopus 로고
    • A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
    • Musto P, Petrucci MT, Bringhen S, et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer. 2008;113:1588-95.
    • (2008) Cancer. , vol.113 , pp. 1588-1585
    • Musto, P.1    Petrucci, M.T.2    Bringhen, S.3
  • 42
    • 34250313823 scopus 로고    scopus 로고
    • A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma
    • DOI 10.1038/sj.leu.2404682, PII 2404682
    • Corso A, Varettoni M, Zappasodi P, et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia. 2007;21:1545-8. (Pubitemid 46965296)
    • (2007) Leukemia , vol.21 , Issue.7 , pp. 1545-1548
    • Corso, A.1    Varettoni, M.2    Zappasodi, P.3    Klersy, C.4    Mangiacavalli, S.5    Pica, G.6    Lazzarino, M.7
  • 43
    • 77957991625 scopus 로고    scopus 로고
    • The use of biochemical markers of bone remodeling in multiple myeloma: A report of the internationalmyelomaworking group
    • Terpos E, Dimopoulos MA, Sezer O, et al. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the InternationalMyelomaWorking Group. Leukemia. 2010;24:1700-12.
    • (2010) Leukemia. , vol.24 , pp. 1700-1702
    • Terpos, E.1    Dimopoulos, M.A.2    Sezer, O.3
  • 44
    • 0036181668 scopus 로고    scopus 로고
    • Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity
    • Yaccoby S, Pearse RN, Johnson CL, et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol. 2002;116:278-90.
    • (2002) Br J Haematol. , vol.116 , pp. 278-270
    • Yaccoby, S.1    Pearse, R.N.2    Johnson, C.L.3
  • 46
    • 58649113384 scopus 로고    scopus 로고
    • Denosumab, a fully human monoclonal antibody to rankl, inhibits bone resorption and increases bmd in knock-in mice that express chimeric (murine/human) rankl
    • Kostenuik PJ, Nguyen HQ, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res. 2009;24:182-95.
    • (2009) J Bone Miner Res. , vol.24 , pp. 182-185
    • Kostenuik, P.J.1    Nguyen, H.Q.2    McCabe, J.3
  • 47
    • 79952761418 scopus 로고    scopus 로고
    • Randomized, doubleblind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
    • Henry DH, Costa L, Goldwasser F, et al. Randomized, doubleblind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125-32.
    • (2011) J Clin Oncol. , vol.29 , pp. 1125-1122
    • Henry, D.H.1    Costa, L.2    Goldwasser, F.3
  • 48
    • 20344396891 scopus 로고    scopus 로고
    • The innate functions of dendritic cells in peripheral lymphoid tissues
    • Steinman RM, Bonifaz L, Fujii S, et al. The innate functions of dendritic cells in peripheral lymphoid tissues. Adv Exp Med Biol. 2005;560:83-97.
    • (2005) Adv Exp Med Biol. , vol.560 , pp. 83-87
    • Steinman, R.M.1    Bonifaz, L.2    Fujii, S.3
  • 49
    • 77950438331 scopus 로고    scopus 로고
    • Activin a promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
    • The first paper addressing the role of activin-A in myeloma-related bone disease
    • Vallet S, Mukherjee S, Vaghela N, et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. ProcNatl Acad SciUS A. 2010;107:5124-9. The first paper addressing the role of activin-A in myeloma-related bone disease.
    • (2010) ProcNatl Acad SciUS A. , vol.107 , pp. 5124-5129
    • Vallet, S.1    Mukherjee, S.2    Vaghela, N.3
  • 50
    • 84867135322 scopus 로고    scopus 로고
    • Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy
    • Forthcoming
    • Terpos E, Kastritis E, Christoulas D, et al. Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Ann Oncol. Forthcoming 2012.
    • (2012) Ann Oncol.
    • Terpos, E.1    Kastritis, E.2    Christoulas, D.3
  • 52
    • 0346363760 scopus 로고    scopus 로고
    • The role of the wnt-signaling antagonist dkk1 in the development of osteolytic lesions in multiple myeloma
    • Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349:2483-94.
    • (2003) N Engl J Med. , vol.349 , pp. 2483-2484
    • Tian, E.1    Zhan, F.2    Walker, R.3
  • 53
    • 33747468221 scopus 로고    scopus 로고
    • Serum concentrations of dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation
    • Politou MC, Heath DJ, Rahemtulla A, et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer. 2006;119:1728-31.
    • (2006) Int J Cancer. , vol.119 , pp. 1728-1721
    • Politou, M.C.1    Heath, D.J.2    Rahemtulla, A.3
  • 54
    • 84872193696 scopus 로고    scopus 로고
    • Dickkopf-1 is elevated in newly-diagnosed, symptomatic patients and in relapsed patients with multiple myeloma. Correlations with advanced disease features: A single-center experience in 284 patients [abstract]
    • Terpos E, Christoulas D, Papatheodorou A, et al. Dickkopf-1 is elevated in newly-diagnosed, symptomatic patients and in relapsed patients with multiple myeloma. correlations with advanced disease features: a single-center experience in 284 patients [abstract]. Haematologica. 2010;95 Suppl 2:384.
    • (2010) Haematologica. , vol.95 , Issue.SUPPL. 2 , pp. 384
    • Terpos, E.1    Christoulas, D.2    Papatheodorou, A.3
  • 55
    • 67650431302 scopus 로고    scopus 로고
    • Anti-dkk1 mab (bhq880) as a potential therapeutic agent for multiple myeloma
    • Fulciniti M, Tassone P, Hideshima T, et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009;114:371-9.
    • (2009) Blood. , vol.114 , pp. 371-379
    • Fulciniti, M.1    Tassone, P.2    Hideshima, T.3
  • 56
    • 61849137831 scopus 로고    scopus 로고
    • Inhibiting dickkopf-1 (dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma
    • Heath DJ, Chantry AD, Buckle CH, et al. Inhibiting dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J Bone Miner Res. 2009;24:425-36.
    • (2009) J Bone Miner Res. , vol.24 , pp. 425-426
    • Heath, D.J.1    Chantry, A.D.2    Buckle, C.H.3
  • 57
    • 22244474640 scopus 로고    scopus 로고
    • Genomic deletion of a longrange bone enhancer misregulates sclerostin in Van Buchem disease
    • Loots GG, Kneissel M, Keller H, et al. Genomic deletion of a longrange bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005;15:928-35.
    • (2005) Genome Res. , vol.15 , pp. 928-925
    • Loots, G.G.1    Kneissel, M.2    Keller, H.3
  • 58
    • 84857440881 scopus 로고    scopus 로고
    • Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women -The six-month effect of risedronate and teriparatide
    • Polyzos SA, Anastasilakis AD, Bratengeier C, et al. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women -The six-month effect of risedronate and teriparatide. Osteoporos Int. 2012;23:1171-6.
    • (2012) Osteoporos Int. , vol.23 , pp. 1171-1176
    • Polyzos, S.A.1    Anastasilakis, A.D.2    Bratengeier, C.3
  • 59
    • 84869509300 scopus 로고    scopus 로고
    • High circulating sclerostin is present in patients with thalassemia-Associated osteoporosis and correlates with bone mineral density
    • Forthcoming
    • Voskaridou E, Christoulas D, Plata E, et al. High circulating sclerostin is present in patients with thalassemia-Associated osteoporosis and correlates with bone mineral density. Horm Metab Res. Forthcoming 2012.
    • (2012) Horm Metab Res.
    • Voskaridou, E.1    Christoulas, D.2    Plata, E.3
  • 60
    • 84864144433 scopus 로고    scopus 로고
    • Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma; reduction postbortezomib monotherapy
    • The first paper addressing the role of sclerostin in myeloma-related bone disease
    • Terpos E, Christoulas D, Katodritou E, et al. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma; reduction postbortezomib monotherapy. Int J Cancer. 2012;131:1466-71. The first paper addressing the role of sclerostin in myeloma-related bone disease.
    • (2012) Int J Cancer. , vol.131 , pp. 1466-1461
    • Terpos, E.1    Christoulas, D.2    Katodritou, E.3
  • 61
    • 84859631972 scopus 로고    scopus 로고
    • Sclerostin: A novel target for intervention in the treatment of osteoporosis
    • Lewiecki EM. Sclerostin: a novel target for intervention in the treatment of osteoporosis. Discov Med. 2011;12:263-73.
    • (2011) Discov Med. , vol.12 , pp. 263-263
    • Lewiecki, E.M.1
  • 62
    • 33750566914 scopus 로고    scopus 로고
    • Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappab ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma
    • Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol. 2006;135:688-92.
    • (2006) Br J Haematol. , vol.135 , pp. 688-682
    • Terpos, E.1    Heath, D.J.2    Rahemtulla, A.3
  • 64
    • 77954253348 scopus 로고    scopus 로고
    • Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid
    • Terpos E, Christoulas D, Kokkoris P, et al. Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. Ann Oncol. 2010;21:1561-2.
    • (2010) Ann Oncol. , vol.21 , pp. 1561-1562
    • Terpos, E.1    Christoulas, D.2    Kokkoris, P.3
  • 65
    • 57849161431 scopus 로고    scopus 로고
    • The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis
    • Terpos E, Kastritis E, Roussou M, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia. 2008;22:2247-56.
    • (2008) Leukemia. , vol.22 , pp. 2247-2246
    • Terpos, E.1    Kastritis, E.2    Roussou, M.3
  • 66
    • 79954426340 scopus 로고    scopus 로고
    • Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase iii vista trial in multiple myeloma
    • The first randomized study confirming the beneficial effect of bortezomib on bone metabolism of myeloma patients who receive front-line therapy
    • Delforge M, Terpos E, Richardson PG, et al. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol. 2011;86:372-84. The first randomized study confirming the beneficial effect of bortezomib on bone metabolism of myeloma patients who receive front-line therapy.
    • (2011) Eur J Haematol. , vol.86 , pp. 372-374
    • Delforge, M.1    Terpos, E.2    Richardson, P.G.3
  • 67
    • 79956042305 scopus 로고    scopus 로고
    • Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients
    • Zangari M, Aujay M, Zhan F, et al. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol. 2011;86:484-7.
    • (2011) Eur J Haematol. , vol.86 , pp. 484-487
    • Zangari, M.1    Aujay, M.2    Zhan, F.3
  • 68
    • 84873566871 scopus 로고    scopus 로고
    • The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-Anabolic activity in addition to anti-myeloma effects
    • doi:10.1038/leu.2012.183
    • Hurchla MA, Garcia-Gomez A, Hornick MC, et al. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-Anabolic activity in addition to anti-myeloma effects. Leukemia. 2012. doi:10.1038/leu.2012.183.
    • (2012) Leukemia.
    • Hurchla, M.A.1    Garcia-Gomez, A.2    Hornick, M.C.3
  • 69
    • 27644523704 scopus 로고    scopus 로고
    • The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of srankl/osteoprotegerin ratio
    • Terpos E, Mihou D, Szydlo R, et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia. 2005;19:1969-76.
    • (2005) Leukemia. , vol.19 , pp. 1969-1966
    • Terpos, E.1    Mihou, D.2    Szydlo, R.3
  • 70
    • 33645725851 scopus 로고    scopus 로고
    • First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma
    • Tosi P, Zamagni E, Cellini C, et al. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Eur J Haematol. 2006;76:399-404.
    • (2006) Eur J Haematol. , vol.76 , pp. 399-390
    • Tosi, P.1    Zamagni, E.2    Cellini, C.3
  • 71
    • 54049156803 scopus 로고    scopus 로고
    • Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
    • Breitkreutz I, Raab MS, Vallet S, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia. 2008;22:1925-32.
    • (2008) Leukemia. , vol.22 , pp. 1925-1922
    • Breitkreutz, I.1    Raab, M.S.2    Vallet, S.3
  • 72
    • 84905057738 scopus 로고    scopus 로고
    • The combination of lenalidomide and dexamethasone (rd) reduces bone resorption in responding patients with relapsed/refractory multiple myeloma (mm) but has no effect on bone formation: Results of a retrospective analysisand a prospective studyon205patients,onbehalf of thegreek myeloma study group [abstract]
    • Terpos E, Christoulas D, Katodritou E, et al. The combination of lenalidomide and dexamethasone (RD) reduces bone resorption in responding patients with relapsed/refractory multiple myeloma (MM) but has no effect on bone formation: results of a retrospective analysisand a prospective studyon205patients,onbehalf of theGreek myeloma study group [abstract]. Haematologica. 2011;96 Suppl 1:65.
    • (2011) Haematologica. , vol.96 , Issue.SUPPL. 1 , pp. 65
    • Terpos, E.1    Christoulas, D.2    Katodritou, E.3
  • 73
    • 33645736007 scopus 로고    scopus 로고
    • Thalidomide derivative cc-4047 inhibits osteoclast formation by down-regulation of pu.1
    • Anderson G, Gries M, Kurihara N, et al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood. 2006;107:3098-105.
    • (2006) Blood. , vol.107 , pp. 3098-3090
    • Anderson, G.1    Gries, M.2    Kurihara, N.3
  • 74
    • 79954427850 scopus 로고    scopus 로고
    • Impact of radiotherapy on pain relief and recalcification in plasma cell neoplasms: Long-Term experience
    • Balducci M, Chiesa S, Manfrida S, et al. Impact of radiotherapy on pain relief and recalcification in plasma cell neoplasms: long-Term experience. Strahlenther Onkol. 2011;187:114-9.
    • (2011) Strahlenther Onkol. , vol.187 , pp. 114-119
    • Balducci, M.1    Chiesa, S.2    Manfrida, S.3
  • 76
    • 0022552036 scopus 로고
    • Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases
    • Price P, Hoskin PJ, Easton D, et al. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol. 1986;6:247-55.
    • (1986) Radiother Oncol. , vol.6 , pp. 247-245
    • Price, P.1    Hoskin, P.J.2    Easton, D.3
  • 77
    • 79952040181 scopus 로고    scopus 로고
    • Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: A multicentre, randomised controlled trial
    • The first randomized study revealing the value of balloon kyphoplasty for the treatment of painful vertebral fractures
    • Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol. 2011;12:225-35. The first randomized study revealing the value of balloon kyphoplasty for the treatment of painful vertebral fractures.
    • (2011) Lancet Oncol. , vol.12 , pp. 225-225
    • Berenson, J.1    Pflugmacher, R.2    Jarzem, P.3
  • 78
    • 70349423596 scopus 로고    scopus 로고
    • Balloon kyphoplasty in malignant spinal fractures: A systematic review and metaanalysis
    • Bouza C, Lopez-Cuadrado T, Cediel P, et al. Balloon kyphoplasty in malignant spinal fractures: a systematic review and metaanalysis. BMC Palliat Care. 2009;8:12.
    • (2009) BMC Palliat Care , vol.8 , pp. 12
    • Bouza, C.1    Lopez-Cuadrado, T.2    Cediel, P.3
  • 80
    • 84872187713 scopus 로고    scopus 로고
    • Management of cancerrelated vertebral compression fracture: Comparison of treatment options; a literature meta-Analysis [abstract]
    • abstract
    • Bhargava A, Trivedi D, Kalva L, et al. Management of cancerrelated vertebral compression fracture: comparison of treatment options; a literature meta-Analysis [abstract]. J Clin Oncol. 2009;27(Suppl:abstract):e20529.
    • (2009) J Clin Oncol. , vol.27 , Issue.SUPPL.
    • Bhargava, A.1    Trivedi, D.2    Kalva, L.3
  • 81
    • 0034857406 scopus 로고    scopus 로고
    • Surgical treatment for pathologic fracture
    • Wedin R. Surgical treatment for pathologic fracture. Acta Orthop Scand Suupl. 2001;72(2p):1-29.
    • (2001) Acta Orthop Scand Suupl. , vol.72 , Issue.2 P , pp. 1-9
    • Wedin, R.1
  • 82
    • 80555149382 scopus 로고    scopus 로고
    • Surgical therapy of skeletal complications in multiple myeloma
    • Utzschneider S, Schmidt H,Weber P, et al. Surgical therapy of skeletal complications in multiple myeloma. Int Orthop. 2011;35:1209-13.
    • (2011) Int Orthop. , vol.35 , pp. 1209-1203
    • Utzschneider, S.1    Schmidt, H.2    Weber, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.